SCHEMBL10264656

SCHEMBL10264656

Cc1ccc(-c2ccccc2Cl)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.56
CCR5 P51681 1/20 0.56
CCR8 P51685 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
DHODH Q02127 2/20 0.51
IDO1 P14902 2/20 0.47
METAP2 P50579 1/20 0.46
KMT2A Q03164 2/20 0.44
CYP3A4 P08684 2/20 0.44
POLB P06746 1/20 0.44
CYP2A6 P11509 1/20 0.44
HSD11B1 P28845 1/20 0.44
NPC1 O15118 2/20 0.41
ALDH1A1 P00352 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497431 0.85 CCR1 (0.52) CCR1CCR5CCR8HDAC6DHODH
SCHEMBL9901550 0.81 CCR1 (0.56) CCR1CCR5CCR8HDAC6DHODH
SCHEMBL8227859 0.80 CCR1 (0.60) CCR1CCR5CCR8HDAC6IDO1
SCHEMBL31039981 0.79 CCR1 (0.48) CCR1CCR5CCR8HDAC6KMT2A
SCHEMBL11957244 0.78 CCR1 (0.58) CCR1CCR5CCR8HDAC6DHODH
SCHEMBL13134510 0.78 CYP11B1 (0.52) CCR1CCR5CCR8HDAC6METAP2
SCHEMBL24513223 0.77 CCR1 (0.56) CCR1CCR5CCR8HDAC6DHODH
SCHEMBL12320877 0.77 CYP11B1 (0.56) CCR1CCR5CCR8HDAC6DHODH
SCHEMBL16627983 0.77 CCR1 (0.56) CCR1CCR5CCR8HDAC6IDO1
SCHEMBL15006447 0.77 CCR1 (0.56) CCR1CCR5CCR8HDAC6IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271622-B1 Heteroaryl derivatives as CFTR Modulators VERTEX PHARMA (US) 2017-10-04 EP disclosed
US-9751890-B2 Heteroaryl derivatives as CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-09-05 US disclosed
US-20170107225-A1 HETEROARYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED 2017-04-20 US disclosed
US-8785445-B2 7-phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA INC. (US) 2014-07-22 US disclosed
US-20120101103-A1 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2012-04-26 US disclosed
WO-2010075200-A1 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2010-07-01 WO disclosed
WO-2009108657-A2 HETEROARYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-09-03 WO disclosed
US-20090221597-A1 HETEROARYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170107225-A1 HETEROARYL DERIVATIVES AS CFTR MODULATORS CFTR, ABCB1, ABCD3 CCR1 3364/4885CCR5 1133/4885CCR8 2801/4885
US-20090221597-A1 HETEROARYL DERIVATIVES AS CFTR MODULATORS CFTR, ABCB1, ABCD3 CCR1 3787/4885CCR5 1286/4885CCR8 3220/4885
US-20120101103-A1 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES PTGDR2, PTGDR, HRH2 CCR1 133/4885CCR5 288/4885CCR8 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.